TMCnet News
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of Commencement of an Investigation Involving Possible Securities Fraud Violations by the Board of Directors of Intercept Pharmaceuticals, Inc. -- ICPTLevi & Korsinsky announces it has commenced an investigation of Intercept Pharmaceuticals, Inc. ("Intercept" or the "Company") (NASDAQ:ICPT) concerning possible violations of federal securities laws. On September 12, 2017, Intercept issued a letter warning physicians against overdosing patients with Ocaliva (obeticholic acid), the Company's treatment for primary biliary cholangitis ("PBC"), advising them that the drug has been tied to liver injuries and death among patients suffering from PBC. Then on September 21, 2017, the Food and Drug Administration issued a Safety Announcement that the drug "is being incorrectly dosed in some patients…resulting in an increased risk of serious liver injury and death." The FDA noted that "In the 13 months after Ocaliva was approved in May 2016, FDA received reports of serious liver injury or death associated with Ocaliva." To obtain additional information, go to: a rel="nofollow" href="http://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.zlkdocs.com%2FICPT-Info-Request-Form-6116&esheet=51689086&newsitemid=20170925006064&lan=en-US&anchor=http%3A%2F%2Fwww.zlkdocs.com%2FICPT-Info-Request-Form-6116&index=1&md5=bec989c869f31db54165dd1b0b3307de" rel="nofollow">http://www.zlkdocs.com/ICPT-Info-Request-Form-6116 or contact Joseph E. Levi, Esq. either via email at [email protected] or by telephone at (212) 363-7500, toll-free: (877) 363-5972. Levi & Korsinsky is a national firm with offices in New York, California, Connecticut and Washington D.C. The firm's attorneys have extensive expertise in prosecuting securities litigation involving financial fraud, representing investors throughout the nation in securities and shareholder lawsuits. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
View source version on businesswire.com: http://www.businesswire.com/news/home/20170925006064/en/ |
